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Reverse Cardio-Oncology: Cancer Development in Patients With
Cardiovascular Disease
Joseph Pierre Aboumsallem, PhD; Javid Moslehi, MD, PhD; Rudolf A. de Boer, MD, PhD
O verwhelming epidemiological evidence demonstrate thatcardiovascular disease and cancer represent major
health burdens in the United States, and they are the leading
causes of mortality.1 According to the National Center for
Health Statistics and the Centers for Disease Control and
Prevention, 616 828 of a total 2 471 984 deaths were
caused by cardiovascular disease and another 134 148 were
caused by cerebrovascular disease.2 Numbers from the
American Cancer Society reveal that 17 million Americans
have a history of cancer3 (representing 5% of the total US
population) and 1.7 million new cases are predicted to be
diagnosed in 2019. Moreover, 660 880 Americans are
expected to die of cancer during 2019, which corresponds to
1660 deaths per day.4 Undoubtedly, these numbers will
further increase as the population ages.
Generally, cardiovascular disease and cancer are viewed as
2 distinct disease entities. The appreciation that cancer and
the cardiovascular disease may coincide mostly comes from
cardiologists who care for patients with cardiovascular
disease because of anticancer treatments (cardio-oncolo-
gists).5,6 Other examples where cancer and cardiovascular
disease meet are cardiac neoplasm or when cancer itself
causes cardiovascular disease, but these are less common.
The substantial increase in the number of cancer survivors
and the spectacular increase in new cancer therapies, often
causing cardiovascular complications, resulted in the founda-
tion of a new discipline called cardio-oncology.7,8 This
subspecialty of cardiology establishes primary and secondary
risk approaches through surveillance as well as interventions
to stratify and diminish cardiovascular risk, to preclude
cardiovascular toxicity and its progression, and to manage the
adverse effects of anticancer treatments.7,8
Less appreciated are potential links between existing
cardiovascular disorders and subsequent malignancy, demon-
strating that patients with cardiovascular disease have higher
cancer risk compared with individuals from the general
population. Consequently, “reverse cardio-oncology” has
started to attract more attention and called for awareness
among physicians for the increased cancer risk in patients
with cardiovascular disease.9–12 It has been suggested that
these 2 disease entities share mutual risk factors, such as
obesity, diabetes mellitus, alcoholism, and tobacco, which
may explain, at least in part, concurrent manifestation.1,11,12
In addition, numerous ancillary mechanisms and pathways
associated with cardiovascular disease were shown to be
involved in cancer pathogenesis. Hence, further studies are
needed to confirm and characterize the shared pathophysi-
ological pathways between cardiovascular disease and
cancer.9,11,12 As for now, clinicians should be aware of the
increased risk and establish recommendations and guidelines
for early diagnosis of malignancy, also and maybe even
stronger so among patients with cardiovascular disease.
This review focuses on reverse cardio-oncology and
highlights clinical studies, meta-analyses, and cohorts that
have evaluated cancer risk in patients with cardiovascular
disease and the risk associated with treatments of cardio-
vascular disease. In addition, this article summarizes mech-
anisms of actions that mediate the cross talk between cancer
and cardiovascular disease.
Incidence of Cancer in Patients With
Cardiovascular Diseases
The association between cardiovascular disease and cancer is
not a novel concept.11–13 In the past few decades, numerous
studies have reported connections between cancer and
hypertension, thromboembolism/stroke, atrial fibrillation
(AF), atherosclerotic cardiovascular disease, myocardial
infarction, and heart failure. Nevertheless, most evidence
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stems from retrospective analyses with mostly noncausal
relationships. In addition, available evidence could be skewed
toward positive associations caused by publication bias.
Because of the potential implications of this concept for
clinicians, and its repercussions for patients with cardiovascu-
lar disease, the following section aims to summarize previous
studies and to present a critical viewpoint of their findings.
Association Between Hypertension and Cancer
Incidence
Several studies have hinted toward an association between
hypertension and cancer incidence. A prospective cohort
study showed that high blood pressure was associated with
cancer incidence and cancer mortality, but this association
was sturdier in men than in women.14 On the basis of 18
studies, a meta-analysis demonstrated a 1.6-fold increase in
the risk of renal cell carcinoma in participants with hyperten-
sion.15 Another study reported a 5% and 7% higher risk for
kidney cancer per every 10–mm Hg higher systolic blood
pressure and diastolic blood pressure, respectively.16 More-
over, a positive correlation between hypertension and risk of
colorectal cancer was estimated, with an 11% higher risk in
individuals with hypertension.16 On the basis of a meta-
analysis of 13 prospective studies, hypertension was linked to
a 7% higher risk of total breast cancer.16,17 Association
between hypertension and risk of prostate cancer was
evaluated in a meta-analysis that used 21 cohort and case-
control studies. Investigators reported a statistically signifi-
cant 8% higher risk. However, this report did not take into
account individual study design and quality.18 Furthermore,
positive associations were observed between hypertension
and risk of other cancers, including endometrial cancer,
squamous cell carcinoma, esophageal adenocarcinoma, and
liver cancer.16 However, these meta-analyses could not
include a large number of prospective studies, and most of
them were performed without comprehensive multivariable
adjustments, which raises concerns about the validity of these
findings. There have been additional meta-analyses for
endometrial cancer, but their conclusions were shaped
without taking into account the study design.19,20 Finally, no
associations were observed between hypertension or blood
pressure and risk of other cancers (namely, lung, cervix, brain,
bladder, pancreas, stomach, and gallbladder).16
The safety of antihypertensive drugs with regard to cancer
incidence has been debated. Many studies and meta-analyses
have evaluated the carcinogenic potential of antihypertensive
drugs. In the ALLHAT (Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial), participants were
randomly assigned to receive chlorthalidone (diuretic treat-
ment), amlodipine (calcium channel blocker), or lisinopril
(angiotensin-converting enzyme inhibitor). The investigators of
ALLHAT evaluated the clinical outcomes by antihypertensive
treatment group and found that the 6-year rate of cancer was
10 per 100 people in the 3 groups. Also, cancer was the main
noncardiovascular cause of death among patients treated with
chlorthalidone, amlodipine, and lisinopril.21 Moreover, can-
desartan, an angiotensin receptor blocker tested for its
effectivity in heart failure in the Candesartan Heart Failure
Assessment of Reduction in Mortality and Morbidity program,
has been linked to increased cancer risk. Of the 371 noncar-
diovascular deaths, 145were cancer related. It was implied that
death attributed to cancer was more frequent in the candesar-
tan group.22 In contrast, other meta-analyses (comprising 70
randomized controlled trials) did not report any difference in
cancer incidence and cancer mortality with antihypertensive
treatments (ARBs [Angiotensin Receptor Blockers], angioten-
sin-converting enzyme inhibitors, b blockers, and diuretics)
versus placebo. However, a slight increase in cancer risk was
observed when angiotensin-converting enzyme inhibitor and
ARB were administrated together.23 The inconsistencies
between meta-analyses could be caused by bias, such as
selection bias, which may lead to inaccurate deductions.
Evaluating the link between antihypertensive treatments and
cancer is critical, considering the difficulty of ruling out the
effects of competing risks. Today, millions of patients with
hypertension are treated with antihypertensive drugs. There-
fore, antihypertensive medications and management require
more consideration as they may influence cancer risk indepen-
dent of hypertension or elevated blood pressures.
Cancer Prevalence Among Stroke Survivors and
Patients With Thromboembolism
Many studies have reported a high prevalence of cancer
deaths among patients who had a stroke.24 The analyses of 3
large cohorts (the OSCP [Oxfordshire Community Stroke
Project], the Lothian Stroke Register, and the IST [Interna-
tional Stroke Trial]) demonstrated that 38% of deaths were
secondary to cancer.24,25 Furthermore, analyses of the data
that were collected as part of the VISP (Vitamin Intervention
for Stroke Prevention) study demonstrated a higher annual
rate of age-adjusted cancer incidence among ischemic stroke
survivors compared with those of the general population.24
This increase was comparable to the slightly higher risk of
cancer in patients with pulmonary embolism and venous
thrombosis.26–28 Previously, the Swedish Inpatient Register
was used to measure cancer incidence among 61 998
patients admitted to the hospital between the years 1965
and 1983 for venous thromboembolism. None of these
patients had previously diagnosed cancer. The general
conclusion was that venous thromboembolism could be a
clear marker of cancer risk, and this assumption was based
on the fact that 4% of cohort patients were diagnosed for
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cancer at the time of the first admission, or during the first
year.28 Although several cohorts showed a continuous
increase of cancer risk for as long as 10 years after the
diagnosis of venous thromboembolism, others demonstrated
a decline in cancer rates after 6 months. This inconsistency
may be caused by the difference in cancer diagnosis
strategies. Another explanation could be the size of the
studies; some were larger, population based, and hospital
record based, and others were smaller and observational.29
Further research would be needed to evaluate the correlation
between stroke or venous thromboembolism and cancer, and
new guidelines should be established for cancer screening in
diagnosed patients.
As for antithrombotic drugs, several studies have reported
their antitumor benefits. Case-control studies suggested that
the use of warfarin may be associated with a reduced
incidence of urogenital malignancies.30,31 It is hypothesized
that the potential antineoplastic effects of warfarin may be
explained by its interaction with mediators of tumor invasion,
such as tissue factor, factor VIIa, and urokinase receptors.27
Furthermore, cancer was detected in 15.8% of patients who
were treated for 6 weeks with oral anticoagulants and in
10.3% of patients who were treated for 6 months, but the
investigators did not demonstrate the percentage of cancer
among untreated participants.27 Findings generated from
another observational study showed that shorter duration of
anticoagulation was associated with a higher cancer risk
compared with longer duration of anticoagulant administra-
tion, which complements the previous findings.29 Data from
randomized trials were used to assess the effects of aspirin
on risks of vascular and cancer events, according to dose and
body weight. The administration of 75 to 100 mg of aspirin
reduced risk of colorectal cancer in participants with a body
weight <70 kg, but this reduction was not observed in people
weighing ≥70 kg. However, with higher aspirin doses
(≥325 mg), similar benefits were observed in individuals
weighing up to 80 kg.32 Aspirin did not affect the total
number of cancer deaths. Nevertheless, the investigators
demonstrated that aspirin diminished cancer-related deaths,
after 5 years of follow-up, in individuals weighing <70 kg. The
ASPREE (Aspirin in Reducing Events in the Elderly) trial was
conducted in the United States and Australia to assess the
effect of aspirin on longevity and all-cause of mortality in
healthy elderly individuals.33 In total, 19 114 participants
were randomly assigned to receive 100 mg aspirin or
placebo. The investigators found that cancer was the main
cause of death in both groups and reported a higher risk of
cancer-related death in the aspirin group compared with the
placebo group (6.7 versus 5.1 events per 1000 person-years).
In addition, the percentages of cancer-death (cancer-death/
all causes of death) were shown to be higher in the aspiring
group in comparison to the placebo group (52.9% versus 46%).
These findings contradict the findings of previous meta-
analyses in which aspirin was shown to have a protective
effect on cancer-related mortality. It is still unclear whether
aspirin has an early or delayed anticancer effect.33 Maybe
cancer physiological features and their molecular patterns
differ among age and weight groups. It has been shown that
aspirin could affect several aspects of cancer, such as
inflammation, angiogenesis, metastasis, and tumor growth.34
Further assessments are still needed to evaluate the mech-
anisms by which these drugs exert their anticancer effects.
AF: Is a Potential Risk Marker for Cancer
AF is the most common form of cardiac arrhythmia,35,36 and it
is linked to other major cardiovascular complications.37–39
Patients with AF are exposed to a substantial risk of death
because of noncardiovascular causes.40 In 1994, the first
report of AF preceding colon cancer was published.41 Twenty
years later, the registry study of all Danish patients was
published and showed that participants had a 2.5% absolute
risk of cancer in the first 3 months after the diagnosis of
AF.42 The investigators found that 57% of the cancer cases
were metastatic at the time of diagnosis, which led them to
conclude that AF, to some extent, may be regarded as a
marker for occult cancer.42 The RE-LY (Randomized Evaluation
Long-Term Anticoagulant Therapy Study) showed that more
than one third of all deaths among participants with AF were
caused by noncardiovascular reasons, and the malignant
tumors were a main cause of these mortalities.40,43 Also, the
relation between AF and cancer was inspected in the “WHS
(Women’s Health Study)”,43 which is a randomized clinical
study that assessed the effects of low-dose aspirin and
vitamin E in the primary prevention of cancer and cardiovas-
cular diseases.44,45 The investigators found that 10% of
participants with new-onset AF developed subsequent
cancer.43 Moreover, AF was substantially associated with
cancer occurrence, and this correlation was not affected by
the administration of aspirin nor by the administration of
vitamin E.43 The risk of cancer was notably higher in women
with paroxysmal or nonparoxysmal AF. The multivariable-
adjusted association between new-onset AF and colon cancer
was statistically significant, but this was not the case for lung
and breast cancers.43 In 2018, a Danish population-based
cohort study evaluated the correlation between AF and risk of
cancer in 26 222 men and 28 879 women free of AF and
cancer at baseline.46 A total of 15% of men and 11.1% of
women with new-onset AF had a subsequent cancer.46 During
the 12-year period after the diagnosis of AF, 23.3% of men
and 19.1% of women were diagnosed with cancer. It was also
noted that for both sexes, the incidence rate of any type of
cancer (any type of cancer or lung and colorectal cancer) was
higher during the first 3 months after the diagnosis of AF.46
DOI: 10.1161/JAHA.119.013754 Journal of the American Heart Association 3
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There were several attempts to solve the question as to
whether AF can be considered as a risk factor for cancer.
Considering the strength of this statement, one should keep
in mind that the term “risk factor” refers to a causal
connection between outcome and exposure. The mechanisms
mediating these associations are perhaps multifactorial and
comprise common risk factors and pathways.47
The updated guidelines for the management of patients
with AF, established by the American Heart Association, the
American College of Cardiology, and the Heart Rhythm
Society, recommend the use of several anticoagulants, such
as warfarin, dabigatran, rivaroxaban, and apixaban.48 The
RE-LY evaluated 2 fixed doses of dabigatran, which is a direct
thrombin inhibitor. The doses were blindly administrated, and
with open-label use of warfarin in participants who had AF.40
Data on mortality showed that 61.41% of deaths were
because of cardiovascular causes and 13.93% were cancer-
related deaths. Also, cancer was the number one noncardio-
vascular cause of death in the dabigatran and warfarin
groups.40 In the ROCKET AF (Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared With Vitamin K Antag-
onism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation), individuals with nonvalvular AF were randomized
to rivaroxaban or dose-adjusted warfarin. Rivaroxaban and
warfarin groups did not exhibit a significant difference in all-
cause mortality. Once again, malignancy-related mortalities
were the highest among the noncardiovascular mortalities in
both groups.49 The ARISTOTLE (Apixaban for the Prevention of
Stroke in Subjects With Atrial Fibrillation) trial randomized
participants with AF to apixaban or warfarin. Apixaban was
superior to warfarin in preventing stroke events, and also in
showing less bleeding and lower mortality.50 Also, malignancy
was the most common cause of death among noncardiovas-
cular deaths in the ARISTOTLE trial (21%).51 Considering the
fact that cancer is the leading noncardiovascular cause of
mortality in most of the trials, the safety of the drugs used for
the management of AF should be assessed continuously to
avoid any further health burden.
Cancer Prevalence in Patients With
Atherosclerotic Cardiovascular Diseases and
Myocardial Infarction
In the modern era, cardiac care in patients with atheroscle-
rotic cardiovascular diseases has markedly improved.52
Invasive and pharmaceutical strategies, adopted by the
long-term cardiovascular care systems, have resulted in a
better prevention of atherosclerotic events and their compli-
cations.53 Trends in causes of mortality in patients after
percutaneous coronary interventions presented a shift from
cardiovascular to noncardiovascular mortality in patients
treated with percutaneous coronary intervention. This
increase in noncardiovascular mortality was attributed to
cancer and other diseases.54 On the basis of the ARIC
(Atherosclerotic Risk in Communities) study, lower cancer
prevalence could be linked to guidelines for the prevention of
atherosclerosis, which means that there are many common
risk factors for cancer and atherosclerotic cardiovascular
alterations.55 A total of 32 095 participants with cardiovas-
cular diseases were enrolled in the SHIP (Sakakibara Health
Integrative Profile) cohort study.52 To evaluate the incidence
of cancer and mortality in patients with atherosclerosis,
participants were segregated on the basis of the presence and
absence of atherosclerotic cardiovascular diseases (namely,
aortic diseases, coronary artery diseases, and peripheral
artery diseases). Cancer prevalence (5% versus 2%) and
mortality (6% versus 3%) were >2-fold higher in patients with
atherosclerotic cardiovascular disease than in patients with
nonatherosclerotic cardiovascular diseases.52 These findings
suggest atherosclerosis as a risk factor for cancer and a
marker of poor prognosis.52 Ultrasound and autopsy assess-
ments demonstrated a strong correlation between atheroscle-
rosis in the carotid and coronary arteries.56,57 Moreover, the
incidence rates of cancer and death were evaluated in
participants with myocardial infarction from data of 4 Danish
registries: The Danish Civil Registration System registry, the
NPR (Danish National Patient Registry), the National Causes of
Death Registry, and the Danish National Prescription Regis-
try.58 All age groups showed that the prevalence rates of cancer
and death were higher among participants with myocardial
infarction.58 The authors reported the highest incidence of
cancer and death during the first year after the diagnosis of
myocardial infarction. In addition, the youngest age group (30–
54 years) exhibited the highest prevalence of colorectal, lung,
and urinary track cancers. However, the risk of these cancers
was decreased in older groups (55–69 and 70–99 years).58
Recent study provided striking insights about the connection
between myocardial infarction–induced heart failure and the
intestinal tumor progression in C57BL/6J-ApcMin/J mice,
which are predisposed to developing precancerous intestinal
tumors.59 Six weeks after the induction of myocardial infarction
or the sham surgery, the investigators reported more and larger
intestinal polyps in C57BL/6J-ApcMin/J mice with failing
hearts.59 At the cellular level, treating HT-29 with a-1-
antichymotrypsin and a-1-antitrypsin, 2 proteins overex-
pressed in the myocardium of C57BL/6J-ApcMin/J mice with
heart failure, resulted in an increased proliferation of these
colorectal cancer cells.59 Finally, the authors showed that heart
failure and inflammation markers were associated with cancer
incidence among participants with heart failure from the
PREVEND (Prevention of Renal and Vascular End-Stage
Disease) study.59
There are many available antiatherosclerosis treatments,
such as statins and antiplatelet agents.60 The relation
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between statins and cancer incidence is still under debate,
although heavily studied. However, the anti-inflammatory
properties of statins could be a starting point to evaluate any
potential link with cancer prevention.11 Revolution and
advances in pharmacological treatments and percutaneous
coronary intervention resulted in better disease management
and significantly decreased mortality.61,62 In the United
States, >85% of coronary stents used are drug-eluting
stents.63 In an integrated analysis on patients recruited in 4
trials,64 patients were randomly assigned to receive a
sirolimus-eluting or a bare-metal stent. Around 60% of deaths
were caused by noncardiovascular causes, and cancer was
among the most frequent noncardiovascular cause of death.64
Moreover, a meta-analysis of 17 stent trials revealed that
cancer, stroke, and infectious diseases were the main
noncardiovascular causes of mortality.65 These findings
suggest a possible connection between stenting and cancer-
related mortality and serve as a basis for further delineations.
To conclude, the epidemiological studies above present
interesting evidence of associations between cardiovascular
disease and the risk of incident cancer. Although these findings
certainly raise significant scientific questions and are of
considerable hypothesis-generating value, it is important to
critically assess and highlight their limitations and validity.Most
evidence originates from associations identified in retrospec-
tives analyses. This has inherent limitations in that causality is
not guaranteed and that retrospective analyses are hampered
by their original design not being powered toward specific
cancer outcomes. In addition, the reported potential procancer
and anticancer effects of cardiovascular medication constitute
contradictory information because the studies reporting them
were not necessarily concordant with each other, even when
the same treatment was being studied. As such, future targeted
and independent studies are required before definitive conclu-
sions can be drawn. Last, to eventually reach clinically relevant
and applicable conclusions, translation of the shared risk
factors and biological processes common to both cancer and
cardiovascular disease to clinical significance is imperative.
Potential Mediators of the Cross Talk
Between Cardiovascular Disease and Cancer
Apart from the above-mentioned potential epidemiological
association, shared biological mechanisms and risk factors
may explain the link between cardiovascular disease and
cancer. Among others, pathways related to inflammation,
clonal hematopoiesis, and hypoxia, as well as circulating
microRNAs, extracellular vesicles, and mediators of cardiac
origin are of interest in this regard. Advancements in our
scientific understanding behind the interactions between
cardiovascular disease and cancer and the exact role of all
the aforementioned factors in this cross talk could potentially
lead to mechanistic insights that can guide future therapeutic
research and clinical decision making. However, the unifica-
tion of the available literature into a quintessential distilled
essence poses considerable challenges, considering the
heterogeneity and disparity of experimental designs, end
points, and scientific messages of the available literature.
Therefore, the following section aims to summarize current
knowledge to bridge past and future research approaches.
Inflammation as a Key Mediator of the
Pathophysiological Connection Between
Cardiovascular Disease and Cancer
Inflammatory pathways contribute to the pathophysiological
features of cardiovascular disease and cancer, and they are
involved in the initiation, progression, and poor prognosis of
the 2 diseases.66 Recent studies emphasized the involvement
of many inflammatory mediators in the EMT (epithelial to
mesenchymal transition), which is as a key step toward
malignant transformation and metastatic behavior.66,67 In the
context of myocardial infarction, necrotic cells intensify
inflammatory responses by releasing danger signals.68 Down-
stream signaling comprises the overactivation of mitogen-
activated protein kinases and the abnormal stimulation of the
nuclear factor-jB. Subsequent overexpression of proinflam-
matory genes (cytokines and chemokines) triggers inflamma-
tory cells, causes oxidative damage and stress, causes DNA
alterations, and modifies the tissue microenvironment, which
can lead to malignant transformation in cells.69 Ischemia
induces several cytokines, including tumor necrosis factor,
which is a potent activator of nuclear factor-jB, a primary
mediator of inflammation in cancer.70,71 Recently, the CANTOS
(Canakinumab Anti-Inflammatory Thrombosis Outcome Study)
has reported promising results, validating inflammation as a
worthwhile target for cardiovascular disease management.72
The investigators showed that canakinumab, an interleukin-1b
neutralizing monoclonal antibody, diminished cardiovascular
events in treated participants.73 Also, total cancermortality and
lung cancer fatalities were substantially lower in the canakinu-
mab group than in the placebo group.72 In addition, it has been
shown that heart failure–associated inflammatory markers,
including C-reactive protein, had a clear predictive value
independently of cancer risk factors.59 The previously
discussed a-1-antichymotrypsin is strongly related to sys-
temic inflammation, and it is one of the proteins that were
elevated in patients with heart failure.59,74,75 The same group
showed that a-1-antichymotrypsin induces colorectal cancer
cell (HT-29) proliferation and tumor growth via protein kinase
B pathways. The investigators reported a significant phos-
phorylation of protein kinase B and ribosomal protein S6 in
HT-29 treated with a-1-antichymotrypsin.59 Assessing
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inflammation as a mechanistic link between the 2 diseases
could offer numerous opportunities and innovative solutions
to reduce their heavy burden.
Clonal Hematopoiesis: A Newly Recognized Link
Between Cardiovascular Disease and Cancer
Somatic genetic mutations are an unescapable consequence
of aging.76,77 This is especially true in the highly proliferative
hematopoietic tissues.78 Genetic alterations in bone marrow
hematopoietic stem cells result in the generation of mutated
leukocyte clones in the peripheral blood.79 This state is not
cancer, but could be considered as a step toward leukemia,
which leads to the term “clonal hematopoiesis of indetermi-
nate potential” (CHiP). In fact, the transition to leukemia
necessitates 2 or 3 consecutive mutations in cancer driver
genes within the same clone.79 Mutations in >20 genes have
been shown to be involved in the transition to myelodysplas-
tic syndrome and acute myeloid leukemia.79 The analysis of
bone marrow–derived mononuclear cells isolated from
patients showed that somatic mutations in hematopoietic
cells, particularly in the genes Ten-Eleven Translocation-2
(TET2) and DNA methyltransferase 3A, were associated with
the development and poor prognosis of heart failure.80
Another study found that mutations in TET2, Janus kinase 2,
and additional sex combs-like were associated with early-
onset myocardial infarction.81 The absence of the CHiP driver
gene TET2 in mice resulted in accelerated atherosclerosis
progression and higher predisposition to cardiac dysfunc-
tion.81,82 Experiments in murine models reported an elevated
IL-1b activity in the presence of CHiP mutations.81,83
Interestingly, dysfunctional TET2 was linked to the activation
of the cytoplasmic supramolecular assembly Nod-like recep-
tor protein 3 inflammasome and inflammatory cytokine
interleukin-6.84,85 It has been suggested that inflammatory
mediators, like interleukin-1b, could affect cardiovascular and
oncological outcomes in individuals with CHiP.86 The CANTOS
revealed that canakinumab, an interleukin-1b antibody,
decreased cardiovascular incidence.87 Interestingly, CHiP-
positive patients (with TET2 mutations) in the CANTOS
benefitted better to canakinumab than participants without
CHiP.88 In addition, the administration of higher dosages of
canakinumab resulted in reduced lung cancer prevalence and
less cancer mortality.72 Furthermore, Nod-like receptor
protein 3 and interleukin-1b can promote tumor growth and
metastasis in several cancer types, such as breast cancer,
lung cancer, and melanoma.89 These findings suggest that
CHiP is a new link between the 2 major diseases. The
mechanisms that underlie this correlation include common
mutations in the oncogenic genes and inflammatory factors
secreted by the mutant leukocytes, as depicted in Figure 1.
Currently, we have more questions than answers and further
investigations are needed to identify the aspects of this
correlation.
Hypoxia Caused by Cardiovascular Disease and
Its Role in Cancer Progression
Hypoxia in patients with cardiovascular disease could be
triggered by insufficient blood flow, hypoxemia, and microvas-
cular-endothelial alterations.5 At the molecular level, hypoxia-
inducible factor 1 is stabilized in response to myocardial
ischemia or infarction.90 Hypoxia-inducible factor 1 is a
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Figure 1. Graphic illustration showing somatic mutations in hematopoietic stem cells as a common path
for cancer and cardiovascular disease.
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endothelial growth factor and is involved in atherosclerosis
progression.91 As discussed in another review,5 in the context
of cancer, hypoxia-inducible factor 1 stimulates tumor growth
and progression by increasing the expression of antiapoptotic
factors and boosting angiogenesis.92–94 Besides, vascular
endothelial growth factor is a key mediator of angiogenesis in
cancer.95 The pathogenesis of several cancer types, including
multiple melanoma and breast cancer, involves numerous
hypoxia-triggered pathways.96,97 Therefore, hypoxia-driven
mechanisms stimulated by cardiovascular disease could
result in malignancies, which makes them another significant
therapeutic target (Figure 2).
Circulating Factors Linking Cardiovascular
Disease to Cancer
Beside recognizing new biomarkers, it is essential to under-
stand their function and evaluate the mechanisms by which
they affect the homeostasis in tissues. Under pathological
conditions, multiple cardiac cells, such as fibroblasts, car-
diomyocytes, and smooth muscle cells, secrete “cardiokines”
into the circulation (Figure 3).98 Because of their endocrine
and paracrine effects, the initiation and progression of many
diseases could be mediated by these cardiac factors. In
ischemic hearts, cardiomyocytes generate many cardiac
factors, including Apelin.99 The latter readapts actin
cytoskeleton organization and increases the level of mem-
brane type 1 matrix metalloprotease, which boosts proteolytic
capacities and migration abilities in colon cancer cells.100
After ischemia or reperfusion (ischemia-reperfusion injury),
fibroblasts produce fibroblast growth factors to enhance cell
survival and cardiac recovery.101,102 The fibroblast growth
factor system mediates epithelial to mesenchymal transition
and promotes tumor angiogenesis and progression.103
Furthermore, ventricular hypertrophy is strongly associated
with the production of another cardiokine, called osteopontin,
which is mainly produced by cardiomyocytes.104 As demon-
strated in another review, osteopontin has been shown to
promote the development of many solid organ tumors via
different pathways.105 Atherosclerotic carotid plaques secrete
growth arrest–specific gene 6, which stimulates survival and
mobility of vascular smooth muscle cells and promotes their
accumulation in the atherosclerotic plaque.106 On the basis of
in vitro studies, growth arrest–specific gene 6 promotes EMT
and cancer invasiveness by activating mitogen-activated
protein kinase and Slug pathways.107 Under hemodynamic
stress, cardiomyocytes secrete atrial natriuretic peptide.108 In
contrast to the other cardiokines discussed in this review,
atrial natriuretic peptide has been demonstrated to have
anticancer effects by targeting many signaling pathways, such
as c-FOS and c-JUN, rat sarcoma, mitogen protein kinase 1/2,
and extracellular signal-regulated kinases 1/2.108 In addition
to cardiokines, the cardiovascular system secretes other
factors and genetic materials, such as microRNAs.
To date, circulating microRNAs have been identified as
biomarkers for diagnostic and prognostic purposes.109 Micro-
RNAs modulate a variety of cellular and biological processes,
including cell proliferation, apoptosis, stemness, senescence,
epithelial to mesenchymal transition, and inflammation.110
Therefore, microRNAs are involved in the pathogenesis of many
human diseases, such as heart diseases,111 vascular dis-
eases,112 and cancers.113 In a context-dependent manner, the
same microRNAs can function as a cardio-microRNA, angio-
microRNA, or onco-microRNA.110 On the basis of previous
experimental screening of microRNA reports and validation
techniques using next-generation sequencing, 4 microRNAs
were identified as cardio-microRNAs as they were upregulated
in human heart disease, and they were as follows: microRNA-
24, microRNA-125b, microRNA-195, and microRNA-214.114–118
Interestingly, the same 4 microRNAs were reported as onco-
genic or tumor suppressors in several cancer subtypes,
including myeloid leukemia, pancreatic cancer, lung adenocar-
cinoma, and prostate cancer.110 Therefore, cardio-microRNAs
are potential connectors between cardiovascular disease and
tumors, which makes them central therapeutic targets. Estab-
lishing databases of circulating microRNAs from cancer and
cardiovascular disease is required to bridge the gap between
the 2 fields. The circulating microRNAs could be conjugated
with the high-density lipoprotein and Argonaute 2 protein or
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Figure 2. Theoretical depiction of the mechanisms by
which hypoxia contributes to cancer growth and angiogenesis.
HIF-1 indicates hypoxia-inducible factor 1; VEGF, vascular
endothelial growth factor.
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In terms of contents, extracellular vesicles are loaded
with distinct components of lipids (phospholipids), proteins
(membrane receptors, enzymes, regulatory proteins, and
adhesion molecules), genetic material (nucleic acids, mRNAs,
and microRNAs), cytokines, chemokines, and growth fac-
tors.123 Extracellular vesicles and their contents are a rapidly
growing area of research in cancer because of their
contribution to oncogenesis, cancer invasiveness, epithelial
to mesenchymal transition, and metastasis, and resistance
to anticancer chemotherapy.124 Extracellular vesicles
involved in cardiovascular diseases share features with the
ones that mediate cancer progression and development
(Figure 3).124 The study by Ohtsuka and colleagues demon-
strated that platelet-derived microvesicles, obtained from
atherosclerotic patients, promote neovascularization by
secreting the regulated upon activation normal T-cell
expressed and secreted.125 The latter was already demon-
strated to be involved in gastric cancer metastasis.126
Regulated upon activation normal T-cell expressed and
secreted may contribute to breast cancer progression by
promoting monocyte migration into tumor sites. Also,
regulated upon activation normal T-cell expressed and
secreted induces the expression of matrix metalloproteinase
9 and stimulates vascularity.127 These data indicate that
extracellular vesicles constitute another connector between
cardiovascular disease and cancer. Detecting, analyzing, and
validating the content and the features of extracellular
vesicles are required to reach an effective therapeutic
application of these particles into the clinical field.
Clinical Implications
Clinical trial data, meta-analyses, and cohort studies consis-
tently confirmed the correlation between cardiovascular
disease and cancer. This serves as a basis for further
investigations to understand mechanisms that mediate this
connection and to identify new therapeutic targets. In the
next few years, we expect that the field of cardio-oncology will
evolve in innovative ways with breakthroughs that will
translate into their use for diagnosis, primary prevention,
treatment, and other clinically relevant end points (Figure 4).
However, inconsistencies between the outcomes of the
published studies are a limitation, and generation of more
high-quality data is needed. The apparent discrepancies may
be caused by differences in cancer and cardiovascular
diagnoses, guidelines, and strategies. Another reason could
be the size and design of the various studies. Besides, cancer
and cardiovascular disease are general terms that refer to
large groups of heterogeneous diseases, which complicates
analyses and interpretations of data. Unifying inclusion
criteria, using stronger diagnostic guidelines, and performing
meticulous end point adjudication will help to improve the
quality of generated data. Also, clinical data registries should
be established in more countries to provide tailored outcomes
based on the characteristics of each population.
Clearly, intense collaborations between oncologists, hema-
tologists, and cardiovascular specialists will be required to
establish guidelines for cardio-oncology and reverse cardio-


















Figure 3. Theoretical depiction of cardiac secretome and its effect on tumor development, mobility, and
metastasis.
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expensive DNA sequencing techniques and stand-alone
initiatives but will be costly and likely not feasible. However,
in the near future, decreased cost of CHiP testing would allow
screening of more individuals, furthering research and collab-
oration efforts.79 In addition to clinical data, we anticipate
that identifying and measuring biomarkers will be essential to
establish clinical prediction models and algorithms to evaluate
the risk of cancer among patients with cardiovascular
diseases. Moreover, the use of cardiovascular disease drugs
requires more attention as it may impact cancer risk
independent of cardiovascular disease. Accordingly, health-
care professionals should modify cardiovascular disease
management guidelines and establish primary and secondary
risk approaches through surveillance as well as interventions
in a concerted effort to reduce cancer risk, manage the
adverse effects of cardiovascular treatments, and allow
optimal cardiovascular and cancer outcomes.
In summary, although classic cardio-oncology focuses on
cardiovascular risk in patients with current or treated cancer,
reverse cardio-oncology deals with inherent cancer risk in
patients with cardiovascular disease. Recent data have raised
more awareness for this phenomenon. Shared risk factors,
pathophysiological pathways, and treatments may explain the
complex relation. Future studies should ensure precise
phenotyping of both disease domains and help to identify
risk assessment and treatment algorithms for patients.
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